Deutivacaftor; Tezacaftor; Vanzacaftor Calcium Patent Expiration
Deutivacaftor; Tezacaftor; Vanzacaftor Calcium was first introduced by Vertex Pharmaceuticals Inc
Deutivacaftor; Tezacaftor; Vanzacaftor Calcium Patents
Given below is the list of patents protecting Deutivacaftor; Tezacaftor; Vanzacaftor Calcium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Alyftrek | US12186306 | Methods of treatment for cystic fibrosis | Jan 10, 2043 | Vertex Pharms Inc |
| Alyftrek | US11873300 | Crystalline forms of CFTR modulators | Aug 13, 2040 | Vertex Pharms Inc |
| Alyftrek | US11066417 | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators | Feb 14, 2039 | Vertex Pharms Inc |
| Alyftrek | US11866450 | Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators | Feb 14, 2039 | Vertex Pharms Inc |
| Alyftrek | US10206877 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | Apr 14, 2035 | Vertex Pharms Inc |
| Alyftrek | US11951212 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | Apr 14, 2035 | Vertex Pharms Inc |
| Alyftrek | US10058546 | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof | Jul 15, 2033 | Vertex Pharms Inc |
| Alyftrek | US9012496 | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof | Jul 15, 2033 | Vertex Pharms Inc |
| Alyftrek | US10047053 | Deuterated CFTR potentiators | May 17, 2032 | Vertex Pharms Inc |
| Alyftrek | US8865902 | Deuterated CFTR potentiators | May 17, 2032 | Vertex Pharms Inc |
| Alyftrek | US9181192 | Deuterated CFTR potentiators | May 17, 2032 | Vertex Pharms Inc |
| Alyftrek | US9512079 | Deuterated CFTR potentiators | May 17, 2032 | Vertex Pharms Inc |
| Alyftrek | US10081621 | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide | Mar 25, 2031 | Vertex Pharms Inc |
| Alyftrek | US11578062 | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide | Mar 25, 2031 | Vertex Pharms Inc |
| Alyftrek | US10646481 | Pharmaceutical composition and administrations thereof | Aug 13, 2029 | Vertex Pharms Inc |
| Alyftrek | US11564916 | Pharmaceutical composition and administrations thereof | Aug 13, 2029 | Vertex Pharms Inc |
| Alyftrek | US8415387 | Modulators of ATP-binding cassette transporters | Nov 12, 2027 | Vertex Pharms Inc |
| Alyftrek | US8324242 | Modulators of ATP-binding cassette transporters | Aug 05, 2027 | Vertex Pharms Inc |
| Alyftrek | US7776905 | Modulators of ATP-binding cassette transporters | Jun 03, 2027 | Vertex Pharms Inc |
| Alyftrek | US7495103 | Modulators of ATP-binding cassette transporters | May 20, 2027 | Vertex Pharms Inc |
| Alyftrek | US7645789 | Indole derivatives as CFTR modulators | May 01, 2027 | Vertex Pharms Inc |
| Alyftrek | US8598181 | Modulators of ATP-binding cassette transporters | May 01, 2027 | Vertex Pharms Inc |
| Alyftrek | US8623905 | Modulators of ATP-binding cassette transporters | May 01, 2027 | Vertex Pharms Inc |
| Alyftrek | US10022352 | Modulators of ATP-binding cassette transporters | Apr 09, 2027 | Vertex Pharms Inc |
| Alyftrek | US10239867 | Modulators of ATP-binding cassette transporters | Apr 09, 2027 | Vertex Pharms Inc |
| Alyftrek | US11639347 | Modulators of ATP-binding cassette transporters | Apr 09, 2027 | Vertex Pharms Inc |
| Alyftrek | US9974781 | Modulators of ATP-binding cassette transporters | Apr 09, 2027 | Vertex Pharms Inc |
| Alyftrek | US8410274 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Alyftrek | US8754224 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Alyftrek | US9670163 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Alyftrek | US9931334 | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Alyftrek | US8354427 | Modulators of ATP-binding cassette transporters | Jul 06, 2026 | Vertex Pharms Inc |
| Alyftrek | US8629162 | Modulators of ATP-binding cassette transporters | Jun 24, 2025 | Vertex Pharms Inc |
Deutivacaftor; Tezacaftor; Vanzacaftor Calcium's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List